CV Sciences Reports 11% Revenue Decline, Widened Net Loss in Q1 2026

summarizeSummary

CV Sciences reported an 11.4% revenue drop and a wider net loss in Q1 2026, signaling ongoing financial challenges despite some operational improvements.

check_boxKey Events

• Revenue Decline

  Q1 2026 revenue decreased 11.4% year-over-year to $3.2 million, primarily due to lower sales volume from restrictive regulations.

• Widened GAAP Net Loss

  The GAAP net loss significantly increased to $0.643 million in Q1 2026, compared to a loss of $0.109 million in Q1 2025.

• Operational Improvements

  Gross margin improved to 48.9% (from 46.0% in Q1 2025), and operating expenses were reduced by 13.3% to $1.9 million.

• Adjusted EBITDA Loss Narrows

  Adjusted EBITDA loss improved to $0.1 million in Q1 2026, compared to a loss of $0.3 million in Q1 2025.

auto_awesomeAnalysis

CV Sciences reported an 11.4% year-over-year revenue decline to $3.2 million and a significantly widened GAAP net loss of $0.643 million for Q1 2026. While the company showed some operational improvements, including a higher gross margin and reduced operating expenses, the overall financial results indicate continued challenges for this micro-cap company, which previously disclosed a going concern warning and has a very low cash balance. These results follow recent highly dilutive debt restructurings and a proposed reverse stock split.